Cancer Management and Research (Oct 2020)

Oncogenic Genetic Alterations in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China

  • Ma Y,
  • Li Q,
  • Du Y,
  • Chen W,
  • Zhao G,
  • Liu X,
  • Li H,
  • Liu J,
  • Shen Z,
  • Ma L,
  • Zhou Y

Journal volume & issue
Vol. Volume 12
pp. 10861 – 10874

Abstract

Read online

Yuhui Ma,1,* Quan Li,2,* Yaxi Du,2,* Wanlin Chen,1 Guanqiang Zhao,1 Xing Liu,2 Hongsheng Li,3 Junxi Liu,3 Zhenghai Shen,4 Luyao Ma,2 Yongchun Zhou4 1Department of Thoracic Surgery I, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital), Kunming 650118, People’s Republic of China; 2Key Laboratory of Lung Cancer Research of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming 650118, People’s Republic of China; 3International Joint Laboratory on High Altitude Regional Cancer of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming 650118, People’s Republic of China; 4Yunnan Cancer Center, The Third Affiliated Hospital of Kunming Medical University, Kunming 650118, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yongchun ZhouYunnan Cancer Center, The Third Affiliated Hospital of Kunming Medical University, Kunming 650118, People’s Republic of ChinaTel/Fax +86-087168172772Email [email protected]: To investigate the impact of oncogenic genetic alterations (GAs) on non-small-cell lung cancer (NSCLC) in southwestern China.Patients and Methods: We first collected 579 pathologically confirmed NSCLC specimens and then used next-generation sequencing (NGS) to evaluate the DNA samples for GAs. Both the tissue and plasma samples were provided by 28 patients. Furthermore, subgroup analyses based on sample type, concordance, and GA type were carried out.Results: GAs were detected by NGS in 61.8% (358/579) of patients. Two hundred and twenty-nine patients (39.6%) harbored EGFR mutations, 63 (10.9%) harbored KRAS mutations, 13 (2.2%) harbored BRAF mutations, 30 (5.18%) harbored ALK fusions, and 13 (2.2%) had ROS1 fusions. We found that females (p < 0.01), nonsmokers (p < 0.001), adenocarcinoma (p < 0.001), and tissue (p = 0.03) had a relatively high EGFR mutation rate. Notably, NSCLC patients from Xuanwei had a significantly different mutational pattern for EGFR in comparison with that of non-Xuanwei patients (higher G719X + S768I mutations and multiple gene alterations, but fewer exon 19 deletion mutations and single gene alterations). We found that adenocarcinoma (p = 0.02), family history of malignancy (p = 0.03), Xuanwei origin (p < 0.001), and tissue (p = 0.04) were associated with a higher number of KRAS mutations. Subgroup analysis showed that ALK (p < 0.001) and ROS1 (p < 0.05) fusions and rare EGFR mutations (p < 0.001) were associated with non-Han ethnic patients.Conclusion: Yunnan NSCLC patients from Xuanwei and non-Han ethnic patients had an obviously unique prevalence of GAs.Keywords: non-small-cell lung cancer, oncogenic genetic alteration, next-generation sequencing

Keywords